½ÃÀ庸°í¼­
»óǰÄÚµå
1403411

ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°, °Ë»ç À¯Çü, °Ë»ç ¹æ½Ä, ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° ¼¼°è ºÐ¼®

Clinical Chemistry Analyzers Market Forecasts to 2030 - Global Analysis By Product, Test Type, Modality, Technology, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ÀÓ»óÈ­ÇÐ ºÐ¼®±â ¼¼°è ½ÃÀåÀº 2023³â 141¾ï7,000¸¸ ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£ µ¿¾È 6.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇØ 2030³â 172¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÓ»óÈ­ÇÐ ºÐ¼®±â´Â Ç÷¾×, ¼Òº¯ ¹× ±âŸ ü¾×ÀÇ ´Ù¾çÇÑ È­ÇÐ ¼ººÐÀ» ºÐ¼®Çϱâ À§ÇØ ¼³°èµÈ ÷´Ü ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀÚµ¿È­ ½Ã½ºÅÛÀº Æ÷µµ´ç, ÄÝ·¹½ºÅ×·Ñ, È¿¼Ò¿Í °°Àº ¹°ÁúÀÇ ³óµµ¸¦ ÃøÁ¤ÇÏ¿© Áúº´À» Áø´ÜÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±× Á¤È®¼º°ú ÀÚµ¿È­¸¦ ÅëÇØ ÀÓ»ó ÇöÀå¿¡¼­ °Ë»ç Áø´ÜÀÇ ½Å·Ú¼º°ú ¼Óµµ¸¦ Çâ»ó½Ãŵ´Ï´Ù.

ij³ª´Ù ¾Ï ÇùȸÀÇ 2021³â º¸°í¼­¿¡ µû¸£¸é 2021³â ij³ª´Ù¿¡¼­ ¾à 229,200¸íÀÇ ¾Ï ȯÀÚ°¡ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¸ÅÀÏ Æò±Õ 628¸íÀÇ Ä³³ª´ÙÀÎÀÌ ¾Ï Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼º Áúȯ Áõ°¡´Â ºÏ¹ÌÀÇ ÀÓ»óÈ­ÇÐ ºÐ¼®±âÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯ Áõ°¡

´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ½ÅÀå Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÌ À¯ÇàÇÔ¿¡ µû¶ó Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ ÀÓ»óÈ­ÇÐ ºÐ¼®ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÓ»óÈ­ÇÐ ºÐ¼®±â´Â ÀÌ·¯ÇÑ Áúº´À» ¸ð´ÏÅ͸µÇÏ°í °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ÀÇ·á ÇöÀå¿¡¼­ÀÇ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¾ÕÀ¸·Îµµ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÇコÄÉ¾î ¾÷°è°¡ ¸¸¼ºÁúȯ Áõ°¡·Î ÀÎÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ³ë·ÂÇÏ´Â °¡¿îµ¥ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼÷·Ã°øÀÇ ºÎÁ·

ÀÓ»óÈ­ÇÐ ºÐ¼®Àº º¹ÀâÇÑ Æ¯¼ºÀ¸·Î ÀÎÇØ Á¤È®ÇÑ Á¶ÀÛ°ú °á°ú ÇØ¼®À» À§ÇØ ¼÷·ÃµÈ Àü¹®°¡°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀåºñÀÇ º¹À⼺À¸·Î ÀÎÇØ ºÐ¼® ±â¼ú, °Ë»ç ÇÁ·ÎÅäÄÝ ¹× µ¥ÀÌÅÍ ºÐ¼®¿¡ ´ëÇÑ ±íÀº ÀÌÇØ¸¦ °¡Áø ÀηÂÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú °ÝÂ÷¸¦ ÇØ¼ÒÇÏ´Â °ÍÀº ÀÓ»óÈ­ÇÐ ºÐ¼®±âÀÇ ÀáÀç·ÂÀ» ±Ø´ëÈ­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ÀÌ´Â ÀÇ·á ÇöÀå¿¡¼­ÀÇ º¸±Þ°ú ÃÖÀûÀÇ ±â´ÉÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ÀÇ·á·ÎÀÇ Àüȯ

¸ÂÃãÇü ÀÇ·á´Â ÀÇ·á °³ÀÔÀ» °³ÀÎÀÇ Æ¯¼º¿¡ ¸Â°Ô Á¶Á¤ÇÏ¿© Ä¡·á È¿°ú¸¦ ÃÖÀûÈ­ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÓ»óÈ­ÇÐ ºÐ¼®±â´Â ȯÀÚÀÇ »ó¼¼ÇÑ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇϰí Á¤È®ÇÑ Áø´Ü°ú Ä¡·á ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü ÀûÀÀÇü ºÐ¼®±â ½ÃÀåÀº È®´ëµÇ´Â Ãß¼¼À̸ç ÀÓ»óÈ­ÇÐ ºÐ¾ßÀÇ Çõ½Å°ú ¼ºÀåÀ» À§ÇÑ À¯¸ÁÇÑ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù.

³ôÀº ¿î¿µºñ¿Í À¯Áöº¸¼ö ºñ¿ë

ÀÓ»óÈ­ÇÐ ºÐ¼®±â´Â º¹ÀâÇÑ ¼³°è, ÷´Ü ±â¼ú, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ¸·Î ÀÎÇØ ³ôÀº ¿î¿µ ¹× À¯Áöº¸¼ö ºñ¿ëÀÌ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®±â´Â Á¤È®¼º°ú ½Å·Ú¼ºÀÌ ¿ä±¸µÇ±â ¶§¹®¿¡ º¹ÀâÇÑ ºÎǰ°ú ¾ö°ÝÇÑ Ç°Áú °ü¸®°¡ ÇÊ¿äÇÕ´Ï´Ù. Á¤±âÀûÀÎ ±³Á¤, À¯Áöº¸¼ö ¹× ÁøÈ­Çϴ ǥÁØÀ» ÁؼöÇÏ´Â µ¥¿¡µµ Áö¼ÓÀûÀÎ ºñ¿ëÀÌ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °æÁ¦ÀûÀÎ ¹®Á¦´Â ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

Äڷγª19ÀÇ À¯ÇàÀº ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. »ýÈ­ÇÐ ºÐ¼®À» Æ÷ÇÔÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ¾ú½À´Ï´Ù. ±×·¯³ª °ø±Þ¸Á È¥¶õ, ÀÇ·á ½Ã¼³ÀÇ ¿¹»ê »è°¨, Àη ºÎÁ·ÀÌ ¹®Á¦°¡ µÇ¾ú½À´Ï´Ù. ½Å¼ÓÇϰí Á¤È®ÇÑ °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ Á߿伺ÀÌ °­Á¶µÇ°í ±â¼ú ¹ßÀü°ú ÇÔ²² ÀÓ»óÈ­ÇÐ ºÐ¼®±â ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀÌ È°¹ßÇÏ°Ô ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ½ÃÀåÀº ȸº¹·ÂÀ» º¸¿©Áá°í, ÁøÈ­ÇÏ´Â ÀÇ·á ȯ°æ¿¡ ÀûÀÀÇϰí, ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ Áø´Ü ¼ö¿ä¿¡ ´ëÀÀÇÏ´Â ¼Ö·ç¼ÇÀ» ¿ì¼±¼øÀ§·Î »ï¾Ò½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ÈÞ´ë¿ë ºÐ¼®±â ºÐ¾ß°¡ °¡Àå Å« ½ÃÀåÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»ó

ÈÞ´ë¿ë ºÐ¼®±â ºÐ¾ß´Â ½Å¼ÓÇϰí Á¤È®ÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÈÞ´ë¿ë ÀÓ»óÈ­ÇÐ ºÐ¼®±â´Â À̵¿ Áß¿¡µµ Ç÷¾× »ùÇÃÀÇ ´Ù¾çÇÑ ÀÇ·á ÆÄ¶ó¹ÌÅ͸¦ ÃøÁ¤ÇÒ ¼ö ÀÖ´Â ¼ÒÇü Áø´Ü Àåºñ´Ù. Æ÷µµ´ç, ÄÝ·¹½ºÅ×·Ñ, ÀüÇØÁú µî ´Ù¾çÇÑ ºÐ¼®¹°ÁúÀ» ÃøÁ¤ÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾î ´Ù¾çÇÑ º´Å»ý¸®¸¦ ½Å¼ÓÇÏ°Ô Áø´ÜÇÏ°í ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÈÞ´ë°¡ °¡´ÉÇϱ⠶§¹®¿¡ ƯÈ÷ ÀÚ¿øÀÌ Á¦ÇÑµÈ Áö¿ªÀ̳ª ¿ø°ÝÁö¿¡¼­ Áø´Ü ´É·Â¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù.

Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»ó

Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ä¡·á ¾à¹° ¸ð´ÏÅ͸µ(TDM)Àº ȯÀÚ¿¡°Ô ÃÖÀûÀÇ ¾à¹° Åõ¿© ¼öÁØÀ» º¸ÀåÇϱâ À§ÇØ ÀÓ»óÈ­ÇÐ ºÐ¼®±â¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®±â´Â »ýü ½Ã·áÀÇ ¾à¹° ³óµµ¸¦ ÃøÁ¤ÇÏ¿© ÀÇ·á Àü¹®°¡°¡ °³º° ȯÀÚÀÇ ¹ÝÀÀ¿¡ µû¶ó Åõ¿© ¿ä¹ýÀ» Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï Çϸç, TDMÀº Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ¸ç ¾à¹° ´ë»çÀÇ º¯µ¿À» ÇØ°áÇÕ´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¾ÆÅÂÁö¿ªÀº ÇコÄɾî ÀÎÇÁ¶ó Áõ°¡, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, Áúº´ Á¶±â ¹ß°ß¿¡ ´ëÇÑ Á߿伺 Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ÆÅÂÁö¿ª¿¡´Â Abbott Laboratories, Siemens Healthineers, Bio-Rad Laboratories, Roche Diagnostics¿Í °°Àº ÁÖ¿ä ±â¾÷µéÀÌ ÁøÃâÇØ ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡´Â Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â°ú ÀÇ·á±â°üÀÇ ³ôÀº Áø·áÁöħ ÀÌÇà·üÀÌ Á¸ÀçÇÕ´Ï´Ù. ¶ÇÇÑ, ¼¼°è ±â¾÷µéÀÇ ³ôÀº R&D ÅõÀÚ¿Í ¹Ì°³¹ßµÈ ±âȸ°¡ Á¸ÀçÇÑ´Ù´Â Á¡µµ ³ôÀº ¼ºÀå µ¿·ÂÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª

ºÏ¹Ì´Â ÇコÄÉ¾î ±â¼úÀÇ ¹ßÀü°ú ¸¸¼º Áúȯ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í, °í·ÉÈ­°¡ ÁøÇàµÇ¸é¼­ Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¾÷°è ÁÖ¿ä ±â¾÷µéÀº °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ Á¦Ç° Çõ½Å°ú Àü·«Àû Á¦ÈÞ¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚµ¿È­ ½Ã½ºÅÛ ¹× ÇöÀå °Ë»ç ¼Ö·ç¼ÇÀÇ µµÀÔÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º Á¦°ø:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÇü ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø, CAGR(Âü°í: Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ±â¼ú ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • ½ÅÇü Äڷγª¹ÙÀÌ·¯½º(COVID-19)ÀÇ ¿µÇâ

Á¦4Àå PorterÀÇ Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå : Á¦Ç°º°

  • º¥Ä¡Å¾ ºÐ¼®±â
  • ÇÃ·Î¾î ½ºÅĵù ºÐ¼®±â
  • ÈÞ´ë¿ë ºÐ¼®±â
  • ¸ðµâ·¯ ºÐ¼®±â
  • ÅëÇÕ ºÐ¼®±â
  • ±âŸ Á¦Ç°

Á¦6Àå ¼¼°èÀÇ ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå : °Ë»ç À¯Çüº°

  • ±âº» ´ë»ç ÆÐ³Î
  • °£ ÆÐ³Î
  • ÀüÇØÁú ÆÐ³Î
  • ÁöÁú ÇÁ·ÎÆÄÀÏ
  • °©»ó¼± ±â´É ÆÐ³Î
  • ½ÅÀå ±â´É ÆÐ³Î
  • Ư¼ö ÆÐ³Î

Á¦7Àå ¼¼°èÀÇ ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå : ¸ð´Þ¸®Æ¼º°

  • ¿ÏÀü ÀÚµ¿ ºÐ¼®±â
  • ¹ÝÀÚµ¿ ºÐ¼®±â
  • POC(Point of Care)(POC) ¾Ö³Î¶óÀÌÀú

Á¦8Àå ¼¼°èÀÇ ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå : ±â¼úº°

  • È¿¼Ò ¾î¼¼ÀÌ ±â¼ú
  • À̿ ¼±Åüº Àü±Ø(ISE) ±â¼ú
  • ºñ»ö ±â¼ú
  • È­ÇÐ ¹ß±¤ ¸é¿ªÃøÁ¤¹ý(CLIA) ±â¼ú
  • Çü±¤ ±â¼ú
  • Àü±âÈ­ÇÐ ¹ÙÀÌ¿À¼¾¼­
  • ºÐÀÚÁø´Ü ±â¼ú

Á¦9Àå ¼¼°èÀÇ ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå : ¿ëµµº°

  • Á¤±âÀû È­ÇÐ °Ë»ç
  • Ư¼öÈ­ÇÐ °Ë»ç
  • Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM)
  • ³»ºÐºñÇп¡ÀÇ ÀÀ¿ë
  • ½ÉÀå ¸¶Ä¿ °Ë»ç
  • °¨¿°Áõ °Ë»ç
  • ±âŸ ¿ëµµ

Á¦10Àå ¼¼°èÀÇ ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Áø´Ü½ÇÇè½Ç
  • ¿¬±¸±â°ü
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú ¿¬±¸¼¾ÅÍ
  • POCT ½Ã¼³
  • ÀçÅà ÇコÄÉ¾î ¼³Á¤

Á¦11Àå ¼¼°èÀÇ ÀÓ»óÈ­ÇÐ ºÐ¼®±â ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦12Àå ÁÖ¿ä ¹ßÀü

  • °è¾à/ÆÄÆ®³Ê½Ê/Çù¾÷/ÇÕÀÛÅõÀÚ(JV)
  • ÀμöÇÕº´(M&A)
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦13Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Mindray Medical International Limited
  • Siemens AG
  • F. Hoffmann-La Roche Limited
  • Danaher Corporation
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • HITACHI
  • Horiba Medical Limited
  • EKF Diagnostics
  • Roche Diagnostics
  • Ortho Clinical Diagnostics
  • Bio-Rad Laboratories
  • Randox Laboratories
  • ELITechGroup
  • DiaSorin
  • Shimadzu Corporation
  • EDAN Instruments
LSH 24.01.12

According to Stratistics MRC, the Global Clinical Chemistry Analyzers Market is accounted for $14.17 billion in 2023 and is expected to reach $17.26 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Clinical Chemistry Analyzers are sophisticated medical instruments designed to analyze various chemical components in blood, urine, and other bodily fluids. These automated systems play a crucial role in diagnosing and monitoring diseases by measuring concentrations of substances like glucose, cholesterol, and enzymes. Their precision and automation enhance the reliability and speed of laboratory diagnostics in clinical settings.

According to the Canadian Cancer Society's 2021 report, about 229,200 new cancer cases will be diagnosed in Canada in 2021, and on average, 628 Canadians are diagnosed with cancer every day. The rising number of chronic diseases in the nation adds to the growth of clinical chemistry analyzers in the North American region.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The need for accurate and timely clinical chemistry analysis intensifies, as chronic conditions such as diabetes, cardiovascular diseases, and kidney disorders become more prevalent. Clinical chemistry analyzers play a crucial role in monitoring and managing these conditions, fostering their widespread adoption in healthcare settings. This trend is likely to persist, contributing to the market's sustained growth as the healthcare industry strives to address the challenges posed by the rising burden of chronic diseases.

Restraint:

Lack of skilled personnel

The complex nature of clinical chemistry analysis requires trained professionals for accurate operation and interpretation of results. The complexity of these instruments demands a workforce with a deep understanding of analytical techniques, laboratory protocols, and data interpretation. Addressing this skill gap becomes crucial for unlocking the full potential of clinical chemistry analyzers, potentially hindering their widespread adoption and optimal functionality in healthcare settings.

Opportunity:

Shift towards personalized medicine

Personalized medicine tailors healthcare interventions to individual characteristics, optimizing treatment efficacy. Clinical chemistry analyzers play a crucial role by providing detailed patient profiles, enabling precise diagnostics and treatment monitoring. As the demand for personalized healthcare rises, the market for advanced and adaptable analyzers is poised for expansion, creating a promising avenue for innovation and growth in the clinical chemistry sector.

Threat:

High operational costs & maintenance expenses

Clinical Chemistry Analyzers incur high operational costs and maintenance expenses due to their intricate design, sophisticated technology, and stringent regulatory requirements. These analyzers demand precision and reliability, necessitating complex components and rigorous quality control. Regular calibration, maintenance, and compliance with evolving standards contribute to ongoing expenses. These financial challenges collectively hamper the market expansion.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the Clinical Chemistry Analyzers market. The increased demand for diagnostic testing, including biochemical analysis, drove market growth. However, disruptions in the supply chain, reduced healthcare facility budgets, and workforce shortages posed challenges. The emphasis on rapid and accurate testing solutions, coupled with ongoing advancements in technology, stimulated innovation in the clinical chemistry analyzers sector. The market exhibited resilience, adapting to the evolving healthcare landscape and prioritizing solutions to address the diagnostic needs arising from the pandemic.

The portable analyzers segment is expected to be the largest during the forecast period

The portable analyzers segment is estimated to have a lucrative growth, due to their rapid and accurate results. Portable clinical chemistry analyzers are compact diagnostic devices that enable on-the-go testing of blood samples for various medical parameters. They are designed to measure a range of analytes, including glucose, cholesterol, and electrolytes, facilitating quick diagnosis and monitoring of various medical conditions. Their portability enhances accessibility to diagnostic capabilities, particularly in resource-limited or remote areas.

The therapeutic drug monitoring (TDM) segment is expected to have the highest CAGR during the forecast period

The therapeutic drug monitoring (TDM) segment is anticipated to witness the highest CAGR growth during the forecast period. Therapeutic Drug Monitoring (TDM) is crucial in Clinical Chemistry Analyzers to ensure optimal medication levels for patients. These analyzers measure drug concentrations in biological samples, enabling healthcare professionals to adjust dosage regimens based on individual patient responses. TDM enhances treatment efficacy, minimizes side effects, and addresses variability in drug metabolism which accelerates the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing healthcare infrastructure, rising prevalence of chronic diseases, and a growing emphasis on early disease detection. It also has the presence of major companies namely Abbott Laboratories, Siemens Healthineers, Bio-Rad Laboratories and Roche Diagnostics. The supportive government initiatives and high implementation of practice guidelines released by healthcare organizations are present across this region. Furthermore, high R&D investment by the global players and presence of unexplored opportunities in this region serve as high growth rendering drivers.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, driven by advancements in healthcare technology and the increasing prevalence of chronic diseases. The region's well-established healthcare infrastructure, coupled with a rising aging population, has led to a higher demand for diagnostic services, boosting the market for clinical chemistry analyzers. Key players in the industry are focusing on product innovation and strategic collaborations to maintain a competitive edge. Further, the adoption of automated systems and point-of-care testing solutions is contributing to market expansion.

Key players in the market:

Some of the key players profiled in the Clinical Chemistry Analyzers Market include Abbott Laboratories, Mindray Medical International Limited, Siemens AG, F. Hoffmann-La Roche Limited, Danaher Corporation, Sysmex Corporation, Thermo Fisher Scientific Inc., HITACHI, Horiba Medical Limited, EKF Diagnostics, Roche Diagnostics, Ortho Clinical Diagnostics, Bio-Rad Laboratories, Randox Laboratories, ELITechGroup, DiaSorin, Shimadzu Corporation and EDAN Instruments.

Key Developments:

In May 2023, Siemens Healthineers launched the Atellica HEMA 570 and 580 Analyzers. These analyzers are designed for high-volume hematology testing. They are intended to streamline testing by integrating automation. The analyzers also have intuitive interfaces and multi-analyzer automation connectivity.

In July 2022, EDAN Instruments launched its POC fluorescence-based CO-OX blood gas and chemistry analysis system, i20, with the capacity to analyze over 45 parameters, covering everything from blood gases to electrolytes to CO-oximetry.

In May 2022, Mindray launched the BS-600M, a powerful, efficient chemistry analyzer that is designed to empower medium-volume laboratories with increased productivity, efficiency, and reliability.

Products Covered:

  • Benchtop Analyzers
  • Floor-standing Analyzers
  • Portable Analyzers
  • Modular Analyzers
  • Integrated Analyzers
  • Other Products

Test Types Covered:

  • Basic Metabolic Panels
  • Liver Panels
  • Electrolyte Panels
  • Lipid Profiles
  • Thyroid Function Panels
  • Renal Function Panels
  • Specialty Panels

Modalities Covered:

  • Fully Automated Analyzers
  • Semi-Automated Analyzers
  • Point-of-Care (POC) Analyzers

Technologies Covered:

  • Enzymatic Assay Technology
  • Ion-Selective Electrode (ISE) Technology
  • Colorimetric Technology
  • Chemiluminescence Immunoassay (CLIA) Technology
  • Fluorescence Technology
  • Electrochemical Biosensors
  • Molecular Diagnostics Technology

Applications Covered:

  • Routine Chemistry Testing
  • Special Chemistry Testing
  • Therapeutic Drug Monitoring (TDM)
  • Endocrinology Applications
  • Cardiac Markers Testing
  • Infectious Disease Testing
  • Other Applications

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Academic Research Centers
  • Point-of-Care Testing (POCT) Facilities
  • Home Healthcare Settings

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Clinical Chemistry Analyzers Market, By Product

  • 5.1 Introduction
  • 5.2 Benchtop Analyzers
  • 5.3 Floor-standing Analyzers
  • 5.4 Portable Analyzers
  • 5.5 Modular Analyzers
  • 5.6 Integrated Analyzers
  • 5.7 Other Products

6 Global Clinical Chemistry Analyzers Market, By Test Type

  • 6.1 Introduction
  • 6.2 Basic Metabolic Panels
  • 6.3 Liver Panels
  • 6.4 Electrolyte Panels
  • 6.5 Lipid Profiles
  • 6.6 Thyroid Function Panels
  • 6.7 Renal Function Panels
  • 6.8 Specialty Panels

7 Global Clinical Chemistry Analyzers Market, By Modality

  • 7.1 Introduction
  • 7.2 Fully Automated Analyzers
  • 7.3 Semi-Automated Analyzers
  • 7.4 Point-of-Care (POC) Analyzers

8 Global Clinical Chemistry Analyzers Market, By Technology

  • 8.1 Introduction
  • 8.2 Enzymatic Assay Technology
  • 8.3 Ion-Selective Electrode (ISE) Technology
  • 8.4 Colorimetric Technology
  • 8.5 Chemiluminescence Immunoassay (CLIA) Technology
  • 8.6 Fluorescence Technology
  • 8.7 Electrochemical Biosensors
  • 8.8 Molecular Diagnostics Technology

9 Global Clinical Chemistry Analyzers Market, By Application

  • 9.1 Introduction
  • 9.2 Routine Chemistry Testing
  • 9.3 Special Chemistry Testing
  • 9.4 Therapeutic Drug Monitoring (TDM)
  • 9.5 Endocrinology Applications
  • 9.6 Cardiac Markers Testing
  • 9.7 Infectious Disease Testing
  • 9.8 Other Applications

10 Global Clinical Chemistry Analyzers Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Diagnostic Laboratories
  • 10.4 Research Institutes
  • 10.5 Pharmaceutical & Biotechnology Companies
  • 10.6 Academic Research Centers
  • 10.7 Point-of-Care Testing (POCT) Facilities
  • 10.8 Home Healthcare Settings

11 Global Clinical Chemistry Analyzers Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 Mindray Medical International Limited
  • 13.3 Siemens AG
  • 13.4 F. Hoffmann-La Roche Limited
  • 13.5 Danaher Corporation
  • 13.6 Sysmex Corporation
  • 13.7 Thermo Fisher Scientific Inc.
  • 13.8 HITACHI
  • 13.9 Horiba Medical Limited
  • 13.10 EKF Diagnostics
  • 13.11 Roche Diagnostics
  • 13.12 Ortho Clinical Diagnostics
  • 13.13 Bio-Rad Laboratories
  • 13.14 Randox Laboratories
  • 13.15 ELITechGroup
  • 13.16 DiaSorin
  • 13.17 Shimadzu Corporation
  • 13.18 EDAN Instruments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦